A New Breakthrough in Obesity Treatment: Promising Phase 3 Data for Retatrutide
For many people struggling with obesity, weight loss is not just about appearance—it is about a range of serious health risks, including knee osteoarthritis pain, sleep apnea that repeatedly wakes them at night, and rising risks of hypertension and diabetes. Recently published results from the TRIUMPH-1 study in the New England Journal of Medicine bring encouraging news: a novel triple hormone receptor agonist called retatrutide has demonstrated unprecedented potential in reducing weight and improving obesity-related complications.
What Is Retatrutide?
Retatrutide is a once-weekly injectable triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. Compared with currently widely used GLP-1 medications (such as semaglutide), it works through multiple metabolic pathways synergistically, potentially achieving more potent weight loss and broader health improvements. Earlier phase 2 trials showed that the drug significantly reduced body weight and improved systolic and diastolic blood pressure, glycated hemoglobin, waist circumference, and lipid levels.
TRIUMPH-1 Study Design
TRIUMPH-1 was a multicenter, randomized, placebo-controlled, double-blind trial conducted across 131 sites in 11 countries, enrolling 2,339 adults with obesity but without diabetes. Participants were randomly assigned to retatrutide 4 mg, 9 mg, 12 mg, or placebo for 80 weeks, followed by a 24-week extension period.
The primary endpoints included:
- Percent change in body weight — assessing overall weight loss
- Change in WOMAC pain score — assessing pain improvement in knee osteoarthritis patients
- Change in apnea-hypopnea index (AHI) — assessing improvement in obstructive sleep apnea
Weight Loss: Up to 25%
Results showed dose-dependent weight loss with retatrutide:
- 4 mg group: mean weight loss of 17.6%
- 9 mg group: mean weight loss of 23.7%
- 12 mg group: mean weight loss of 25.0%
- Placebo group: mean weight loss of only 3.9%
Between-group differences versus placebo were -13.7, -19.8, and -21.0 percentage points, respectively, with all comparisons highly statistically significant (P<.001). This means patients receiving the 12 mg dose lost an average of one-quarter of their body weight.
Significant Relief for Knee Osteoarthritis Pain
In the subpopulation of patients with obesity and knee osteoarthritis, retatrutide also performed impressively. Changes in WOMAC pain scores were:
- 4 mg group: -3.2 points
- 9 mg group: -3.5 points
- 12 mg group: -3.6 points
- Placebo group: -1.9 points
Between-group differences were -1.6 and -1.8 points (both P<.001), demonstrating that retatrutide can significantly reduce pain and improve quality of life in knee osteoarthritis patients.
Substantial Improvement in Sleep Apnea
For patients with obstructive sleep apnea, retatrutide delivered even more striking improvements. Changes in apnea-hypopnea events per hour were:
- 4 mg group: reduction of 22.9 events/hour
- 9 mg group: reduction of 34.3 events/hour
- 12 mg group: reduction of 31.7 events/hour
- Placebo group: reduction of 9.9 events/hour
Between-group differences were -24.4 and -21.9 (both P<.001). This means patients treated with retatrutide saw nighttime apnea events drop from frequent occurrences to near-normal levels, with the potential for fundamental improvements in sleep quality and daytime sleepiness.
Safety and Tolerability
The safety profile of retatrutide was consistent with previous phase 2 trials. The most common adverse events were gastrointestinal reactions (such as nausea and diarrhea), mostly mild to moderate, similar to existing GLP-1 medications. Additionally, hypotension symptoms were observed but were dose-dependent and more common in patients concurrently taking antihypertensive medications.
Implications for Obesity Treatment Philosophy
Study author Dr. Ania Jastreboff, Professor of Medicine at Yale School of Medicine, noted: "Obesity is a heterogeneous disease, and medications that act through multiple mechanisms may provide the possibility of greater weight reduction and broader health improvement." The research team further suggested that given the substantial weight loss achieved with retatrutide, future obesity treatment might follow the model of diabetes management by setting defined therapeutic targets (such as HbA1c <6.5%), rather than merely pursuing a relative percentage change in weight.
What This Means for Patients
For people dealing with obesity, joint pain, and sleep apnea simultaneously, this study sends a positive signal: effective weight loss treatment can not only reduce body weight itself but also simultaneously improve multiple obesity-related complications. If you are managing your weight or related health issues, it is recommended to develop a personalized plan under medical guidance and regularly monitor key indicators such as blood pressure, blood sugar, and sleep quality.
The Xiaoshu Health App can sync with Apple Health to track relevant metrics, helping you continuously monitor changes in weight, blood pressure, sleep, and more in your daily life, providing valuable reference data for medical consultations and health management.